“If small biotech companies like ours are forced to scale back or shut down, it will not just be a loss for scientific ...
Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Biohaven (NYSE:BHVN) with a Buy recommendation.
Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...
Investor's Business Daily on MSN2d
Biohaven Just Hurdled An FDA Setback — And Its Moving LinesBiohaven stock hurdled its 50-day and 200-day lines Tuesday after the FDA granted its SCA treatment a speedier review time.
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with ...
The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...
Biohaven (BHVN) is jumping 10% after the FDA agreed to review the company’s potential treatment for a rare disease.
Biohaven boasts a robust pipeline with late-stage molecules, but a Hold rating reflects its high market cap and uncertain ...
Biohaven has won Food and Drug Administration priority review for its application seeking approval of troriluzole for adults with spinocerebellar ataxia, a group of rare, genetic neurological ...
Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback